Additionally, tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 dual agonist, has proven efficacy in weight reduction and was recently approved by the Food and Drug Administration (FDA) for treating type 2 diabetes (T2D) and obesity (5,23,24). This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.